Login to Your Account


AZ therapy faces down Veltassa

Astrazeneca plc's long-time-coming approval of Lokelma (sodium zirconium cyclosilicate) oral suspension for adults with hyperkalemia puts another weapon in the hands of doctors, and there's more coming down the pike, albeit far off.

more »


Our Habitat for All Things Science
GWAS in Chinese population implicates immune system in Alzheimer's disease

A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.

The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.

READ MORE »

Opinion


Partners in Focus